Dinutuximab
- TRADE NAME: Unituxin (United Therapeutics)
- INDICATIONS: High-risk neuroblastoma in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and isotretinoin (13-cis-retinoic acid), in pediatric patients who achieve at least a partial response to prior first-line multiagent, multimodality therapy
- CLASS: GD2-binding monoclonal antibody, Monoclonal antibody
- HALF-LIFE: 10 days
FDA APPROVAL DATE: 03/10/2015
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:None known
PREGNANCY CATEGORY: N/A
May cause fetal harm
SERIOUS INFUSION REACTIONS AND NEUROTOXICITY
See full prescribing information for complete boxed warning.
Please login to see the rest of this drug profile
SKIN.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
HEMATOLOGIC.
LOCAL.
RENAL.
RESPIRATORY.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of dinutuximab in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 07/31/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric